ABT Molecular Imaging, Inc.



King Fahad Medical City to install “Dose on Demand” Biomarker Generator from ABT

KnoxvilleTNUNITED STATESApril 302012 – King Fahad Medical City (KFMC), the largest medical complex in Saudi Arabia, will employ the latest technology for PET Radiopharmaceutical production”.

Tom Welch, CEO of ABT Molecular Imaging, stated “KFMC is recognized as a technical innovator in the Middle East, and we are honored to be working with such a prestigious institution. The ABT solution provides KFMC the platform for advanced biomarker production, and enables expansion of both their PET clinical and research capabilities”. KFMC will be the premier reference site for the Biomarker Generator in the Middle East

The “Dose on Demand” Biomarker Generator will provide on-site production of PET biomarkers in a room directly adjacent to the PET/CT Scanner. The system is the first to provide a completely integrated solution including a compact cyclotron, integrated micro-chemistry, and automated quality control, for individual biomarker dose production. “By integrating a total solution for PET biomarker production in a very compact 30 square meter area, the ABT system allows us to provide this capability at the point of care, and on-demand, whenever these biomarkers are needed” stated Dr. Abdullah Alamro, Radiation oncologist and CEO at KFMC.

KFMC is a 1400-bed healthcare complex in the capital city of Riyadh, providing a comprehensive range of services, including the first facility in the region to offer advanced proton therapy.

About ABT Molecular Imaging, Inc.

ABT Molecular Imaging has developed a Generator which produces unit doses of molecular imaging drugs for positron emission tomography (PET) eliminating the need for chemistry and physics knowhow. The Generator consists of a small positive ion cyclotron, a micro-chemistry unit and an automated Quality Control Module. Historically, the production of PET drugs required significant technology infrastructure, expense and made it necessary for the staff to be exposed to significant radiation doses. Generally these issues have limited the use of PET to large academic medical centers and pharmaceutical manufacturers in specific geographies. The company was founded in 2006 by industry experts in the molecular imaging industry.

For all media enquires please contact:

Rick Rippin, Director of Sales

Telephone: 407-615-0776/Email: rrippin@abt-mi.com

ABT Molecular Imaging, founded in 2006, develops and markets the new Biomarker Generator, providing single dose production of FDG and other PET Biomarkers to the Molecular Imaging markets. The Company is headquartered in Knoxville, Tennessee. For more information, call 1.858.587.3641 or visit www.advancedbiomarker.com